Late Cardiac Toxic Effects Associated With Treatment Protocols for Hodgkin Lymphoma in Children

Lo AC, Liu A, Liu Q, Yasui Y, Castellino SM, Kelly KM, Hererra AF, Friedberg JW, Friedman DL, Schwartz CL, Pei Q, Kessel S, Bergeron-Gravel S, Dama H, Roberts K, Constine LS, Hodgson DC. Late Cardiac Toxic Effects Associated With Treatment Protocols for Hodgkin Lymphoma in Children. JAMA Netw Open. 2024 Jan 2;7(1):e2351062. doi: 10.1001/jamanetworkopen.2023.51062. PubMed PMID: 38241048; PubMed Central PMCID: PMC10799264.

In this cohort study of 2563 patients with HL treated in 4 consecutive Children’s Oncology Group clinical trials between 2002 and 2022, the 30-year cumulative incidence of grade 3 to 5 cardiac disease was estimated to decrease from 10% in the first trial to 6% in the last trial. These findings suggest that evolutions in HL treatment are associated with a net reduction in late cardiac disease.